KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Inventory (2016 - 2025)

Pacific Biosciences Of California (PACB) has 16 years of Inventory data on record, last reported at $54.0 million in Q1 2025.

  • For Q1 2025, Inventory changed N/A year-over-year to $54.0 million; the TTM value through Mar 2025 reached $54.0 million, changed N/A, while the annual FY2024 figure was $58.8 million, 3.67% up from the prior year.
  • Inventory reached $54.0 million in Q1 2025 per PACB's latest filing, down from $58.8 million in the prior quarter.
  • Across five years, Inventory topped out at $67.6 million in Q2 2023 and bottomed at $16.3 million in Q1 2021.
  • Average Inventory over 5 years is $46.4 million, with a median of $54.0 million recorded in 2025.
  • Peak YoY movement for Inventory: surged 104.81% in 2022, then rose 3.67% in 2024.
  • A 5-year view of Inventory shows it stood at $24.6 million in 2021, then soared by 104.81% to $50.4 million in 2022, then rose by 12.49% to $56.7 million in 2023, then rose by 3.67% to $58.8 million in 2024, then decreased by 8.08% to $54.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $54.0 million in Q1 2025, $58.8 million in Q4 2024, and $65.7 million in Q3 2024.